Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Zeller · SciRah

Researcher profile · Semantic Scholar

C. Zeller

Share profile

C. Zeller — researcher profile on SciRah

h-index: 28
Works: 55
Citations: 11K

Most-cited papers

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
M. Packer, S. Anker, J. Butler, G. Filippatos +35 more
2020New England Journal of Medicine3,877 citations Open access
Semantic Scholar
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
S. Anker, J. Butler, G. Filippatos, J. Ferreira +37 more
2021New England Journal of Medicine3,303 citations Open access
Semantic Scholar
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
I. Tikkanen, K. Narko, C. Zeller, A. Green +3 more
2014Diabetes Care446 citations
Semantic Scholar
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
M. Ridderstråle, K. R. Andersen, C. Zeller, Gabriel Kim +2 more
2014The Lancet Diabetes and Endocrinology339 citations
Semantic Scholar
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
J. Rosenstock, A. Jelaska, C. Zeller, G. Kim +2 more
2015Diabetes, obesity and metabolism239 citations Open access
Semantic Scholar
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
S. Anker, J. Butler, G. Filippatos, Waheed Jamal +8 more
2019European Journal of Heart Failure218 citations Open access
Semantic Scholar
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
M. Packer, S. Anker, J. Butler, G. Filippatos +15 more
2020Circulation210 citations Open access
Semantic Scholar
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
W. Abraham, J. Lindenfeld, P. Ponikowski, P. Agostoni +23 more
2020European Heart Journal182 citations
Semantic Scholar
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
Sven Kohler, C. Zeller, H. Iliev, S. Kaspers
2017Advances in Therapy180 citations Open access
Semantic Scholar
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
J. Butler, S. Anker, G. Filippatos, M. Khan +16 more
2021European Heart Journal162 citations Open access
Semantic Scholar
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
F. Zannad, J. Ferreira, S. Pocock, C. Zeller +9 more
2020Circulation161 citations Open access
Semantic Scholar
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
M. Packer, J. Butler, G. Filippatos, Waheed Jamal +8 more
2019European Journal of Heart Failure156 citations Open access
Semantic Scholar
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction
M. Packer, J. Butler, F. Zannad, G. Filippatos +14 more
2021Circulation151 citations Open access
Semantic Scholar
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
G. Mancia, C. Cannon, I. Tikkanen, C. Zeller +4 more
2016HYPERTENSION108 citations Open access
Semantic Scholar
Empagliflozin and Major Renal Outcomes in Heart Failure.
M. Packer, J. Butler, F. Zannad, S. Pocock +7 more
2021New England Journal of Medicine78 citations Open access
Semantic Scholar
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
J. Ferreira, S. Anker, J. Butler, G. Filippatos +6 more
2021European Journal of Heart Failure75 citations Open access
Semantic Scholar
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
J. Butler, M. Packer, G. Filippatos, J. Ferreira +6 more
2021European Heart Journal64 citations Open access
Semantic Scholar
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
M. Packer, J. Butler, C. Zeller, S. Pocock +6 more
2023Circulation61 citations Open access
Semantic Scholar
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Kohler, S. Kaspers, Afshin Salsali, C. Zeller +1 more
2018Diabetes Care57 citations
Semantic Scholar
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
G. Savarese, N. Sattar, J. Januzzi, S. Verma +10 more
2019Circulation53 citations Open access
Semantic Scholar
THE WIN RATIO METHOD IN HEART FAILURE TRIALS: LESSONS LEARNT FROM EMPULSE
S. Pocock, J. Ferreira, T. Collier, C. Angermann +12 more
2023European Journal of Heart Failure47 citations Open access
Semantic Scholar
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
J. Ferreira, J. Butler, F. Zannad, G. Filippatos +7 more
2022Journal of the American College of Cardiology46 citations Open access
Semantic Scholar
Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review.
J. Gregson, Gregg W. Stone, Deepak L. Bhatt, Milton Packer +4 more
2023Journal of the American College of Cardiology45 citations Open access
Semantic Scholar
Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
William T. Abraham, P. Ponikowski, Martina Brueckmann, C. Zeller +8 more
2019European Journal of Heart Failure45 citations Open access
Semantic Scholar
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
D. Yabe, A. Yasui, L. Ji, Moon-Kyu Lee +8 more
2018Journal of Diabetes Investigation41 citations Open access
Semantic Scholar
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
M. Ridderstråle, Robbyna Svaerd, C. Zeller, Gabriel Kim +2 more
2013Cardiovascular Diabetology39 citations Open access
Semantic Scholar
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
J. Butler, Muhammad Shahzeb Khan, J. Lindenfeld, W. Abraham +7 more
2022JACC. Heart failure37 citations Open access
Semantic Scholar
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
M. Packer, F. Zannad, J. Butler, G. Filippatos +6 more
2021European Journal of Heart Failure28 citations Open access
Semantic Scholar
Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
M. Packer, J. Butler, G. Filippatos, F. Zannad +6 more
2020European Journal of Heart Failure28 citations Open access
Semantic Scholar
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline
J. Januzzi, J. Ferreira, M. Böhm, S. Kaul +8 more
2019European Journal of Heart Failure22 citations
Semantic Scholar
Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
I. Neeland, Darren K Mcguire, B. Eliasson, M. Ridderstråle +4 more
2015Diabetes Therapy22 citations Open access
Semantic Scholar
A Bayesian Network View on Nested Effects Models
C. Zeller, H. Fröhlich, A. Tresch
2008EURASIP J. Bioinform. Syst. Biol.21 citations Open access
Semantic Scholar
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
S. Anker, T. Siddiqi, G. Filippatos, F. Zannad +6 more
2022European Journal of Heart Failure20 citations Open access
Semantic Scholar
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
P. Pellicori, A. Ofstad, D. Fitchett, C. Zeller +5 more
2020ESC Heart Failure20 citations Open access
Semantic Scholar
Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?
J. Gregson, S. Pocock, Stefan D. Anker, Deepak L. Bhatt +3 more
2024Journal of the American College of Cardiology19 citations Open access
Semantic Scholar
P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Butler Javed, S. Anker, M. Brueckmann, G. Filippatos +7 more
2021Heart & Lung17 citations
Semantic Scholar
Empagliflozin Improves Blood Pressure in Patients with Type 2 Diabetes (T2DM) and Hypertension
I. Tikkanen, K. Narko, C. Zeller, A. Green +4 more
201314 citations Open access
Semantic Scholar
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis.
J. Ferreira, F. Zannad, J. Butler, G. Filippatos +7 more
2023JACC. Heart failure10 citations Open access
Semantic Scholar
Patient-Reported Outcomes as End Points in Heart Failure Trials.
Javed Butler, Muhammad Shariq Usman, Charu Gandotra, Ali Salman +5 more
2025Circulation9 citations
Semantic Scholar
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
M. S. Khan, J. Butler, S. Anker, G. Filippatos +12 more
2022Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease8 citations Open access
Semantic Scholar
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
J. Butler, G. Savarese, N. Sattar, J. Januzzi +10 more
2019Journal of the American College of Cardiology7 citations Open access
Semantic Scholar
Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)
S. Anker, F. Zannad, Javed Butler, G. Filippatos +8 more
2019Diabetologie und Stoffwechsel7 citations
Semantic Scholar
Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure
F. Zannad, Javed Butler, G. Filippatos, S. Pocock +6 more
2021Diabetologie und Stoffwechsel6 citations
Semantic Scholar
EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
F. Zannad, B. J. Kraus, C. Zeller, S. Pocock +5 more
2021Journal of the American Society of Nephrology4 citations
Semantic Scholar
P2629Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial
P. Pellicori, A. Ofstad, D. Fitchett, C. Zeller +5 more
2019European Heart Journal4 citations
Semantic Scholar
Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
M. Ridderstråle, K. R. Andersen, C. Zeller, G. Kim +2 more
20144 citations
Semantic Scholar
BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on one or ≥2 antihypertensive agents – further insights from a dedicated 24h ABPM study
G. Mancia, C. Cannon, I. Tikkanen, C. Zeller +5 more
20153 citations
Semantic Scholar
Effect of empagliflozin on diabetic ketoacidosis in patients with type 2 diabetes: pooled clinical trial data
S. Lund, F. Solimando, Sven Kohler, C. Zeller +1 more
2017Diabetologie und Stoffwechsel2 citations
Semantic Scholar
Abstract 16474: BP Reduction With the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin in Type 2 Diabetes is Similar in Treatment Naïve as in Those on One or ≥ 2 Antihypertensive Agents - Further Insights From a Dedicated 24h ABPM Study
G. Mancia, C. Cannon, I. Tikkanen, C. Zeller +5 more
20142 citations
Semantic Scholar
Design of the Effect of EMPaglifozin on ExeRcise ability and HF-symptoms, In patients with chronic heArt faiLure (EMPERIAL) trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction
W. Abraham, Stefan D. Anker, Afshin Salsali, Barbara Peil +6 more
2019Diabetologie und Stoffwechsel1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Brueckmann×21
Invite
M. Brueckmann — researcher profile on SciRah
M. Packer×20
Invite
M. Packer — researcher profile on SciRah
F. Zannad×20
Invite
F. Zannad — researcher profile on SciRah
J. Butler×19
Invite
J. Butler — researcher profile on SciRah

×19

Invite

G. Filippatos — researcher profile on SciRah

J. Ferreira×17

Invite

J. Ferreira — researcher profile on SciRah

Invite

S. Anker — researcher profile on SciRah

Waheed Jamal×12

Invite

Waheed Jamal — researcher profile on SciRah

Invite

S. Pocock — researcher profile on SciRah

Afshin Salsali×11

Invite

Afshin Salsali — researcher profile on SciRah

Invite

S. Anker — researcher profile on SciRah

Invite

J. Schnee — researcher profile on SciRah